Curated CRC research — accessible, accurate, actionable

The CRC Digest

Monday, July 20, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  First-line immunotherapy outperforms chemotherapy in MSI-H/dMMR metastatic colorectal cancer

  A meta-analysis of phase III trials confirms immune checkpoint inhibitors show superior progression-free and overall survival compared to standard chemotherapy as first-line treatment for patients with MSI-H or dMMR metastatic disease. (J Gastrointest Cancer)

• ◇ RESEARCH

  Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapy

  Liquid biopsy detected concurrent Y96S and Y96C mutations in a patient with KRAS G12C-mutated metastatic CRC who progressed after 9.3 months of KRAS G12C inhibitor monotherapy; these polyclonal alterations were absent at baseline and indicate convergent evolution under treatment pressure. (Oncologist)

• ◇ RESEARCH

  Machine learning model predicts liver metastasis risk after colorectal cancer surgery

  A multicenter study developed an AI-integrated model using clinical, laboratory, and CT imaging data to predict which stage I–III CRC patients will develop metachronous liver metastasis within 5 years after radical surgery. (Abdom Radiol)

• ◇ RESEARCH

  Review highlights accessible blood-based biomarkers for CRC detection

  A systematic review synthesizes circulating transcriptomic and proteomic biomarkers detectable by widely available RT-PCR and ELISA platforms, aiming to bridge the gap between high-throughput research and clinically scalable diagnostics. (Crit Rev Clin Lab Sci)

These findings underscore the importance of molecular profiling and personalized treatment strategies in colorectal cancer care.